ATRX and central nervous system cancer: In recent neuro-oncological and neurosurgical applications, DKI has mostly been evaluated for its capability of glioma grading and differentiation of gliomas from other intra-axial brain tumors [31,32,33,34], its role in molecular profiling such as its correlation with IDH1/2 mutations, ATRX or Ki-67 expression [33,35], its potential as a biomarker [36], or its capability of detecting microstructural changes related to white matter alterations [37,38,39].